← Back to Search

Monoclonal Antibodies

pembrolizumab for Endometrial Cancer

Phase 2

Waitlist Available

Led By Haider Mahdi, MD

Research Sponsored by Haider Mahdi

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new cancer treatment combination in women with endometrial cancer or other solid tumors.

Eligible Conditions

Recurrent Endometrial Cancer
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response

Secondary outcome measures

Adverse Events Related to Treatment

Clinical Benefit

Duration of Response (DOR)

+3 more

Side effects data

From 2022 Phase 3 trial • 1274 Patients • NCT02220894

12%

Weight decreased

Diarrhoea

Arthralgia

Constipation

Haemoptysis

Hypothyroidism

Aspartate aminotransferase increased

Decreased appetite

Alanine aminotransferase increased

Nasopharyngitis

Bronchitis

Anaemia

Cough

Asthenia

Pruritus

Pneumonia

Headache

Blood alkaline phosphatase increased

Rash

Leukopenia

Hyperglycaemia

Pneumonia bacterial

Myalgia

Subdural haemorrhage

Nausea

Malaise

White blood cell count decreased

Upper respiratory tract infection

Hypertension

Pyrexia

Dyspnoea

Back pain

Chest pain

Haematemesis

Tumour associated fever

Hyperthyroidism

Lymph gland infection

Upper gastrointestinal haemorrhage

Oedema peripheral

100%

80%

60%

40%

20%

Study treatment Arm

Pembrolizumab Second Course

Pembrolizumab

Chemotherapy (SOC Treatment)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Pembrolizumab + SitravatinibExperimental Treatment2 Interventions

Standard of care pembrolizumab 200 mg IV combined with oral sitravatinib 100 mg oral QD every 21 days until disease progression, unacceptable toxicities or complete response.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

FDA approved

Sitravatinib

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Haider MahdiLead Sponsor

5 Previous Clinical Trials

193 Total Patients Enrolled

Mirati Therapeutics Inc.Industry Sponsor

70 Previous Clinical Trials

8,205 Total Patients Enrolled

Haider Mahdi, MDPrincipal InvestigatorUPMC Hillman Cancer Center

4 Previous Clinical Trials

134 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of participants taking part in this clinical experiment?

"Confirmative. According to the records published on clinicaltrials.gov, this investigation is currently looking for enrollees and was first posted September 8th 2022 with a subsequent edit occurring on September 12th 2022. A total of 30 participants are required from one medical centre."

Answered by AI

Has pembrolizumab earned recognition from the Food and Drug Administration?

"While pembrolizumab has been proven to be reasonably safe, its efficacy is yet to be confirmed. As such, this drug's safety was rated at 2 on a scale of 1-3."

Answered by AI

Is recruitment currently open for this experiment?

"Yes, clinicaltrials.gov details suggest this medical research is actively seeking participants for enrollment. It was initially posted on September 8th 2022 and last updated on the 12th of that month. 30 patients are required at one site for completion of the trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Haider Mahdi 2022. "Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05419817.